Death-associated protein-like 1 (DAPL1) (DAPL1)

Death-associated protein-like 1 (DAPL1) is a small, intrinsically disordered protein that is structurally related to the Death-associated protein (DAP) family, though it lacks a formal death domain (UniProt Q96GN5). It is predominantly expressed in epithelial tissues, including the skin and the retinal pigment epithelium, where it plays a critical role in early epithelial differentiation and the regulation of programmed cell death (PubMed: 11022044). Genetic studies have strongly linked DAPL1 polymorphisms to the risk of age-related macular degeneration (AMD) and primary open-angle glaucoma, suggesting a protective or regulatory role in ocular tissue homeostasis (PubMed: 25643384). In the context of cancer, DAPL1 expression is often dysregulated, influencing tumor cell proliferation, migration, and the epithelial-to-mesenchymal transition (EMT) in colorectal and breast carcinomas (PubMed: 30217955). The protein is also involved in the autophagic pathway, potentially acting as a scaffold or regulator during cellular stress responses (PubMed: 28438714). Although no clinical-stage drugs currently target DAPL1, its involvement in significant degenerative and oncogenic pathways makes it an attractive candidate for future therapeutic intervention. Therapeutic strategies might involve small molecule inhibitors to block its pro-tumorigenic functions or gene therapy to restore its protective role in the retina. Understanding the precise molecular interactions of DAPL1 remains a priority for developing targeted therapies that can modulate its activity without disrupting normal epithelial maintenance.

Other names

Early epithelial differentiation-associated proteinEEDADAP-like protein 1

Currently, there are no established pharmacological mechanisms of action as no drugs are approved for this target; however, therapeutic strategies focus on the modulation of apoptotic signaling and epithelial differentiation pathways (PubMed: 25643384).